contact@king-theme.com   +1 123-456-7890
    Former German firm bringing more biotech business to San Antonio

    Former German firm bringing more biotech business to San Antonio

    San Antonio’s successful recruitment of Cytocentrics more than a year ago has led to another economic win that could further enhance the city’s role in the global bioscience arena.

    The company, which recently changed its name to CytoBioScience Inc., has acquired a Birmingham, Alabama-based biotech firm called Soluble Therapeutics that will look to establish roots here over the next 12 months.

    CytoBioScience officials believe the “multimillion-dollar purchase” could draw more companies and talent to the Alamo City. At a minimum, it will likely attract more attention from entities that could be looking for a new home.

    “What this does is deepen the biotech footprint in San Antonio. And whenever you do that, you just don’t know what shore the ripples from these waves will land on,” CytoBioScience CEO Dr. James Garvin told me.

    CytoBioScience, which decided to move its headquarters from Germany to San Antonio in 2015, develops and manufactures devices that allow other researchers, medical institutions and pharmaceutical companies to better understand how human cells react to medicine. The company’s acquisition of Soluble Therapeutics is part of a larger strategic shift aimed at broadening its product platform.

    Soluble Therapeutics Managing Director Sharney Logan said the acquisition will allow CytoBioScience to expand its technology to more global markets. As part of the agreement, the Alabama biotech firm will change its name to SolubleBioScience and move its operations, including its scientific team, to San Antonio.

    Garvin expects other bioscience companies will take note of San Antonio’s latest win.

    “This will continue to raise the awareness of what is already happening in the city,” he said.

    CytoBioScience leadership hinted recently that the company was looking to widen its reach. And the acquisition of Soluble may not be its last move.

    But the deal could trigger other economic opportunities as San Antonio continues to build up its bioscience industry assets, as well as its reputation across the United States and abroad.

    “San Antonio is already one of the best places in the world for biotechnology,” Garvin said. “But we need to continue to beat our chests.”

    Soluble Therapeutics Acquired by CytoBioscience

    Soluble Therapeutics Acquired by CytoBioscience

    SAN ANTONIO–(BUSINESS WIRE)–CytoBioscience, Inc. has purchased Birmingham, Alabama-based Soluble Therapeutics and will move the company’s operations to its San Antonio location.

    The deal closed November 1, according to James Garvin, Chief Executive Officer of CytoBioscience. Details of the multi-million dollar purchase price were not disclosed.

    “The Soluble Therapeutics team has created a business offering that aligns very well with our technology and work to positively impact the efforts of drug development enterprises and researchers across the globe,” he said. “This deepens our product offering in the market and also strengthens our scientific team. We look forward to integrating their team and delivering an expanded set of capabilities to the biotechnology and pharmaceutical industries.”

    “Combining forces with CytoBioscience will dramatically increase our business, as it will provide additional service opportunities to our existing customers,” said Sharney Logan, Managing Director of Soluble Therapeutics. “Additionally, this transaction will provide new opportunities to expand our technology in global markets. As part of the acquisition, Soluble Therapeutics will also be changing its name to Soluble BioScience to reflect its increased capacities.”

    Soluble employs 8 people and the plans are for the company to move to San Antonio within the next year.

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc (now Soluble BioScience) was founded in 2008 to commercialize the HSC™ Technology which is licensed from the University of Alabama at Birmingham. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability.

    About CytoBioscience, Inc.

    CytoBioscience creates and manufactures devices that represent a convergence of bioscience, nano science, microchip development, algorithms and engineering. The company’s devices allow other researchers, medical institutions and pharmaceutical companies to better understand how human cells react to medicine. CytoBioscience was founded in Germany and moved its headquarters and manufacturing to San Antonio in 2015.

    Contacts
    for CytoBioscience, Inc.
    Jim Dublin, 210-387-3113
    jdublin@dublinstrategies.com

    Soluble Therapeutics Closes on Second Investment Round

    Soluble Therapeutics Closes on Second Investment Round

    by John McCarter, MS

    Birmingham, AL- December 2013

    – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO and product development company specializing in formulation optimization for protein-based Bioscience, announces that it has secured a second round of investment to support the expansion of its formulation development business. This expansion is necessary to meet continued demand for the company’s large molecule formulation service, as well as to accommodate two new research collaborations, one with a global Pharmaceutical Contract Manufacturing Organization (CMO) and one with a large US based pharmaceutical company, that could lead to exclusive licensing deals for the HSCTM Technology.

    The investment comes from the Targeted Technology Fund II out of San Antonio, TX – a group that has participated in prior funding rounds for the company. Soluble Therapeutics’ CEO, Dr. Joseph Garner, states “This funding represents a vote of confidence in the work that Soluble Therapeutics is doing and will allow us to continue expanding upon our initial success. We are very excited about the research collaborations kicking off in 2014 and further demonstrating the value of the HSCTM Technology in the marketplace.”

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years of combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSCTM Technology. For additional information visit http://www.soluble-Therapeutics.com

    About the HSCTM Technology

    The HSCTM Technology is a combination of high-throughput protein screening instrumentation and an artificial neural network. The instrumentation performs Self-Interaction Chromatography (SIC) to measure the effects of additives and excipients on the B22 value of proteins in solution. Positive B22 values are correlated with increased solubility and stability for the protein under study. By performing high-throughput SIC, the HSCTM Technology can do the work of 4,000 formulation assays in approximately one month. The HSCTM Technology is available on a contract research basis, or the HSCTM System can be purchased for use in laboratories across the world.

    Contact:
    John McCarter, MS
    Director – Business Development
    Soluble Therapeutics, Inc.
    Tel: (205) 451-9964

    Soluble Therapeutics  to Launch HSC™ Technology at BioProcess International Conference

    Soluble Therapeutics to Launch HSC™ Technology at BioProcess International Conference

    by John McCarter, MS

    Birmingham-based Soluble Therapeutics, Inc, today announced the official launch of its high-throughput second viral coefficient determination system, HSC™ Technology, at the IBC BioProcess International Conference in Providence, RIOctober 8-12.

    HSC™ Technology was developed by Dr. Bill Wilson, former Chairman, Chemistry Department at Mississippi State University, and former NASA astronaut, Dr. Larry DeLucas, Director of the Center for Biophysical Sciences & Engineering at the University of Alabama Birmingham. Doctors Wilson and DeLucas have collaborated for the last two decades on the development of the HSC™Technology. http://www.youtube.com/watch?v=J1PwehpiV-I

    “Conventional methods used to identify formulations promoting solubility and stability of proteins often cost hundreds of thousands of dollars,” said Dr. Joseph N. Garner, CEO, Soluble Therapeutics. Inc. “HSC™ Technology accelerates the formulation process, achieving in a month what can take a team of scientists a year or longer to achieve. Since significantly less protein is required for optimization, HSC™ is an incredibly efficient way to get past the formulation bottleneck.”

    Companies developing biotherapeutics face the challenge of keeping therapeutic proteins soluble and stable at high concentrations. The HSC™system helps researchers and manufacturers overcome this challenge by reducing time and costs, while accelerating the progression of candidates through the development pipeline.

    HSC™ Technology is a self-contained, automated, chromatographic system that conducts high-throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.

    The HSC™Instrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.

    Soluble Therapeutics, Inc. has received over $1 million in grant funding from the National Institutes of Health, which is being utilized to advance applications of the HSC™ Technology.

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process, by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics.

    Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first company to introduce protein formulation solutions that deliver the price and performance advantages of the HSC™ Technology.

    Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC™ Technology for Protein Formulation

    Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC™ Technology for Protein Formulation

    by John McCarter, MS

    Birmingham, AL – 1 June 2012 – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO specializing in formulation optimization for protein-based therapeutics announces a Phase II award of approximately $1MM from the NIH Small Business Technology Transfer Program (STTR).

    After closing a $1MM round of venture funding in the summer of 2011, this new infusion of capital will allow Soluble Therapeutics to accelerate the development and commercialization of the HSCTMTechnology for protein formulation – a technology that is able to identify optimized formulations for protein-based therapeutics in 45 days while using minimal quantities of protein. This technology has the power to greatly reduce the time and resources required to prepare protein-based drugs for clinical development.

    Dr. Larry DeLucas, Director of the UAB Center for Biophysical Sciences and Engineering is the principal investigator on the project and is one of the founding scientists of Soluble Therapeutics. Dr. Delucas states that he is “extremely pleased with the direction the company has taken with this technology and this Phase II award is proof of its commercial viability and immediate success in a challenging formulation market.”

    “This grant is another testament to the excellent work in biotechnology that is coming out of Soluble Therapeutics, UAB and being fostered at Innovation Depot,” said Steven Ceulemans, Vice President of Innovation and Technology at the Birmingham Business Alliance, the Birmingham region’s leading economic development agency. “It demonstrates the value of the HSCTM Technology and the strength of the Birmingham region’s innovation infrastructure.”

    Soluble Therapeutics’ CEO, Dr. Joseph Garner states that “our formulation service, utilizing the HSCTM Technology, continues to perform well in commercial engagements and this funding from the NIH further validates our technology as a new standard in protein formulation. We look forward to completing the development of the 3rdgeneration of the HSCTM Instrument that will be made available for purchase to the biopharmaceutical industry.”

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability, bringing transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSCTM Technology. For additional information visit www.solublebioscience.com.

    Soluble Therapeutics, Inc. closes a $1MM Round of VC Funding led by The Birmingham Technology Fund, Greer Capital, and Targeted Technology Fund

    Soluble Therapeutics, Inc. closes a $1MM Round of VC Funding led by The Birmingham Technology Fund, Greer Capital, and Targeted Technology Fund

    by John McCarter, MS

    Birmingham, AL – 11 July 2011 – Soluble Therapeutics, Inc. a Birmingham, Alabama–based CRO specializing in formulation optimization for protein-based therapeutics announces the closing of a $1MM investment that includes funds from The Birmingham Technology Fund, Greer Capital, and Targeted Technology Fund. This investment represents confidence from a group that has a strong track record of investing in companies with solid growth histories and clear paths to profitability focused on serving the needs of the pre-clinical drug discovery market.

    This investment will allow Soluble Therapeutics, Inc. to complete the company expansion and continue its mission to accelerate the HSCTMTechnology into the marketplace.

    Soluble Therapeutics’ CEO, Dr. Joseph Garner states that “this investment comes at a perfect time for Soluble Therapeutics; it will allow us to immediately expand our capacity to meet market demand for our formulation services.”

    Targeted Technology Fund is the newest investor to back Soluble Therapeutics with the closing of this round , and it is led by Managing Partner, Dr. Paul Castella, a seasoned entrepreneur with a history of investing in biotechnology companies with the potential to meet aggressive profitability goals. “This investment in Soluble Therapeutics represents our confidence in the HSCTM Technology and its ability to capture market share quickly” states Dr. Castella.

    About Soluble Therapeutics, Inc.

    Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics’ management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first to introduce protein formulation solutions that deliver the price and performance advantages of the HSCTM Technology. For additional information visit www.soluble-therapeutics.com